Barclays PLC Boosts Stake in Cryoport, Inc. (NASDAQ:CYRX)

Barclays PLC raised its position in shares of Cryoport, Inc. (NASDAQ:CYRX - Free Report) by 272.9% in the third quarter, according to its most recent filing with the SEC. The firm owned 81,417 shares of the company's stock after purchasing an additional 59,582 shares during the quarter. Barclays PLC owned approximately 0.16% of Cryoport worth $660,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in the company. Dynamic Technology Lab Private Ltd acquired a new stake in shares of Cryoport during the third quarter worth $82,000. Hsbc Holdings PLC acquired a new position in Cryoport in the second quarter valued at $92,000. Intech Investment Management LLC bought a new stake in Cryoport during the third quarter valued at $105,000. The Manufacturers Life Insurance Company grew its holdings in Cryoport by 9.5% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 17,683 shares of the company's stock worth $122,000 after acquiring an additional 1,534 shares during the period. Finally, XTX Topco Ltd bought a new position in shares of Cryoport in the 2nd quarter worth about $198,000. Institutional investors own 92.90% of the company's stock.

Insider Buying and Selling at Cryoport

In other news, Director Ramkumar Mandalam sold 7,369 shares of the stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $7.46, for a total value of $54,972.74. Following the completion of the sale, the director now directly owns 59,497 shares of the company's stock, valued at $443,847.62. This represents a 11.02 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Jerrell Shelton sold 50,000 shares of the firm's stock in a transaction that occurred on Thursday, November 21st. The shares were sold at an average price of $6.51, for a total value of $325,500.00. Following the completion of the transaction, the chief executive officer now owns 731,897 shares in the company, valued at $4,764,649.47. This represents a 6.39 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 109,869 shares of company stock valued at $735,673. Corporate insiders own 10.10% of the company's stock.

Cryoport Stock Up 0.1 %

NASDAQ CYRX traded up $0.01 during mid-day trading on Friday, hitting $7.50. The company's stock had a trading volume of 217,091 shares, compared to its average volume of 297,536. The firm has a market capitalization of $370.73 million, a price-to-earnings ratio of -2.22 and a beta of 1.58. The company's 50 day simple moving average is $7.68 and its 200 day simple moving average is $7.85. The company has a current ratio of 5.70, a quick ratio of 5.32 and a debt-to-equity ratio of 0.48. Cryoport, Inc. has a twelve month low of $5.32 and a twelve month high of $20.10.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the company. Roth Mkm decreased their target price on Cryoport from $18.00 to $15.00 and set a "buy" rating for the company in a research note on Friday, November 8th. Guggenheim assumed coverage on shares of Cryoport in a research report on Thursday, December 19th. They set a "buy" rating and a $11.00 price objective for the company. Needham & Company LLC reiterated a "buy" rating and set a $11.00 target price on shares of Cryoport in a research report on Friday. Finally, UBS Group raised their price target on shares of Cryoport from $7.00 to $9.00 and gave the stock a "neutral" rating in a report on Friday, October 18th. Three investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $12.29.

About Cryoport

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.